Program
CDR132L
A development code. Also written as “CDR132L (i.v.)” and “CDR132L (s.c.)”.
Its studies are mostly in Heart Failure · Myocardial Infarction, led by Novo Nordisk.
Furthest: phase 2, since Apr 20, 20226 company-led studies, 3 open or runningNext primary completion: Dec 31, 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordisk | 63 open or running | phase 2since Apr 20, 2022 | Jul 23, 2019 | Dec 31, 2026phase 1 · NCT07656454 |
- Named in Novo Nordisk’s own pipeline as
CDR132L
, phase 2, as of Nov 5, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 23, 2019First study: phase 1 study in Heart FailureFirst studyNCT04045405 · 28 enrolled · United Kingdom
- Apr 20, 2022Phase 2 study in Myocardial InfarctionNCT05350969 · 294 enrolled · Czechia, Germany, Greece and more
- Jun 29, 2023Phase 2 study in Heart FailureNCT05953831
- May 15, 20252 phase 2 studies in Heart FailureNCT06979375, NCT06979362
- Jun 14, 2026Phase 1 study in Heart FailureNCT07656454 · 32 planned · Germany
Ahead
- Dec 31, 2026Primary completion: phase 1 study in Heart FailureNCT07656454
- May 16, 2027Primary completion: phase 2 study in Heart FailureNCT06979375
- Nov 16, 2027Primary completion: phase 2 study in Heart FailureNCT06979362
TargetBeta
“CDR132L is a synthetic antisense oligonucleotide (ASO) and a selective inhibitor of microRNA-132-3p (miR-132).”study text, read by Claude · the study
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07656454Heart Failure · Germany | 1 | Recruiting | Dec 31, 2026 | 32 |
| NCT06979362Heart Failure · United States, Canada, Germany and more | 2 | Recruiting | Nov 16, 2027 | 200 |
| NCT06979375Heart Failure · Australia, Czechia, Germany and more | 2 | Recruiting | May 16, 2027 | 200 |
| NCT05953831Heart Failure | 2 | Withdrawn | Sep 30, 2025 | 0 |
| NCT05350969Myocardial Infarction · Czechia, Germany, Greece and more | 2 | Completed | Sep 26, 2024 | 294 |
| NCT04045405Heart Failure · United Kingdom | 1 | Completed | Jan 31, 2020 | 28 |
How it is read
Names in the registry
- “CDR132L”, 5 entries
- “CDR132L (i.v.)”, 1 entry
- “CDR132L (s.c.)”, 1 entry
Codes read as this program: CDR132L.
Conditions, from the studies’ own filings
- Heart Failure, 5 studies
- Myocardial Infarction, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.